Format

Send to

Choose Destination
Future Cardiol. 2005 Mar;1(2):235-43. doi: 10.1517/14796678.1.2.235.

Adrenomedullin in heart failure: potential therapeutic implications.

Author information

1
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand. chris.charles@chmeds.ac.nz

Abstract

Adrenomedullin (AM) may play a role in the pathophysiology of heart failure. Plasma levels of AM are raised in cardiovascular disease in proportion to severity of cardiac dysfunction, and plasma AM levels measured in acute myocardial infarction and heart failure are a useful prognostic indicator of outcome. AM administration in both experimental and human heart failure induces a beneficial spectrum of biological action including reduced arterial and atrial pressures, improved cardiac output, inhibition of plasma aldosterone and preservation or augmentation of urinary sodium excretion. Combining AM administration with either angiotensin-converting enzyme inhibition or neutral endopeptidase inhibition results in augmentation of the hemodynamic and renal effects of the individual treatments. Manipulating the AM system may prove beneficial as an adjunctive therapeutic strategy in cardiac disease.

PMID:
19804168
DOI:
10.1517/14796678.1.2.235

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center